TLD | No TLD | |
---|---|---|
Diagnosis | ||
HIE—stage 2 | 2 (5.7%) | 33 (94.3%) |
HIE—stage 3 | 30 (93.8%)* | 2 (6.2%)* |
P/IVH—grade III | 5 (27.8%) | 13 (72.2%) |
P/IVH—grade IV | 30 (68.2%)* | 14 (31.8%)* |
Outcome | ||
Survived | 18 (23.1%)† | 66 (98.5%)† |
GOS 1 | 4 (22.2%)† | 36 (54.5%)† |
GOS 2 | 4 (22.2%) | 7 (10.6%) |
GOS 3 | 0 | 6 (9.1%) |
GOS 4 | 8 (44.4%)† | 6 (9.1%)† |
N/A | 2 (11.1%) | 11 (16.7%) |
Died‡ | 60 (76.9%)† | 1 (1.5%)† |
For diagnosis, percentages are expressed as a proportion of each category with or without TLD.
For neurological outcome, percentages are expressed as a proportion of surviving infants within each outcome category. Survival/Deaths are expressed as a proportion of all infants with/without TLD.
*p<0.05 (Fisher's exact test) (comparing frequency of treatment limitation decisions between infants with stage 3 versus stage 2 HIE, and grade IV versus grade III P/IVH).
†p<0.05 (Fisher's exact test) (comparing frequency of outcome between infants with/without TLD).
‡Death includes in-hospital and post-discharge deaths.
GOS, Glasgow Outcome Scale; HIE, hypoxic–ischaemic encephalopathy; P/IVH, peri-/intraventricular haemorrhage; TLD, treatment limitation discussion.